[PDF][PDF] Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside

MA Ghonim, DF Boyd, T Flerlage… - Journal of Clinical …, 2023 - Am Soc Clin Investig
In recent years, there has been an explosion of interest in how fibroblasts initiate, sustain,
and resolve inflammation across disease states. Fibroblasts contain heterogeneous subsets …

[HTML][HTML] The multifaceted therapeutic role of N-acetylcysteine (NAC) in disorders characterized by oxidative stress

G Raghu, M Berk, PA Campochiaro… - Current …, 2021 - ncbi.nlm.nih.gov
Oxidative stress, which results in the damage of diverse biological molecules, is a ubiquitous
cellular process implicated in the etiology of many illnesses. The sulfhydryl-containing …

An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline

G Raghu, B Rochwerg, Y Zhang… - American journal of …, 2015 - atsjournals.org
Background: This document updates the American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …

Idiopathic pulmonary fibrosis (IPF): an overview

SL Barratt, A Creamer, C Hayton… - Journal of clinical …, 2018 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy

X Bai, Q Chen, F Li, Y Teng, M Tang, J Huang… - Nature …, 2024 - nature.com
Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges
such as resistance to shear force damage, mucus penetration, cellular internalization, rapid …

Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis Clinical … - … England Journal of …, 2012 - Mass Medical Soc
Background A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has
been widely used as a treatment for idiopathic pulmonary fibrosis. The safety and efficacy of …

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

G Raghu, HR Collard, JJ Egan, FJ Martinez… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits

GF Rushworth, IL Megson - Pharmacology & therapeutics, 2014 - Elsevier
Abstract N-acetyl-l-cysteine (NAC) has long been used therapeutically for the treatment of
acetaminophen (paracetamol) overdose, acting as a precursor for the substrate (l-cysteine) …

Targeting oxidative stress as a therapeutic approach for idiopathic pulmonary fibrosis

C Estornut, J Milara, MA Bayarri, N Belhadj… - Frontiers in …, 2022 - frontiersin.org
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an
abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis …

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

PW Noble, C Albera, WZ Bradford, U Costabel… - The Lancet, 2011 - thelancet.com
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …